146 related articles for article (PubMed ID: 1828173)
21. CGS 16949A, a new aromatase inhibitor in the treatment of breast cancer--a phase I study.
Beretta KR; Hoeffken K; Kvinnsland S; Trunet P; Chaudri HA; Bhatnagar AS; Goldhirsch A; Cavalli F
Ann Oncol; 1990 Nov; 1(6):421-6. PubMed ID: 2150591
[TBL] [Abstract][Full Text] [Related]
22. Novel aromatase inhibitors.
Bhatnagar AS; Häusler A; Schieweck K; Browne LJ; Bowman R; Steele RE
J Steroid Biochem Mol Biol; 1990 Nov; 37(3):363-7. PubMed ID: 2147860
[TBL] [Abstract][Full Text] [Related]
23. The effect of the aromatase inhibitor, rogletimide (pyridoglutethimide), on guinea pig adrenal cell steroidogenesis and placental microsomal aromatase activity: comparison with aminoglutethimide and CGS 16949A.
Newton CJ; Mehta A; Dowsett M
J Steroid Biochem Mol Biol; 1991 Nov; 39(5A):723-7. PubMed ID: 1659868
[TBL] [Abstract][Full Text] [Related]
24. Effect of CGS 16949A plus tamoxifen on induced mammary tumours in rats.
Tominaga T; Yoshida Y; Shimozuma K; Hayashi K; Kosaki G
Eur J Cancer; 1990; 26(5):600-3. PubMed ID: 2144748
[TBL] [Abstract][Full Text] [Related]
25. CGS 16949A, a new nonsteroidal aromatase inhibitor: effects on hormone-dependent and -independent tumors in vivo.
Schieweck K; Bhatnagar AS; Matter A
Cancer Res; 1988 Feb; 48(4):834-8. PubMed ID: 2962734
[TBL] [Abstract][Full Text] [Related]
26. Antitumor effects of a nonsteroidal aromatase inhibitor (CGS 16949A) on 7, 12-dimethylbenz[alpha]anthracene-induced mammary tumors in rats.
Iino Y; Sugamata N; Owada S; Tago T; Sato H; Yokoe T; Maemura M; Morishita Y; Horiuchi R
Jpn J Clin Oncol; 1991 Jun; 21(3):153-9. PubMed ID: 1834875
[TBL] [Abstract][Full Text] [Related]
27. An in vitro method to determine the selective inhibition of estrogen biosynthesis by aromatase inhibitors.
Häusler A; Schenkel L; Krähenbühl C; Monnet G; Bhatnagar AS
J Steroid Biochem; 1989 Jul; 33(1):125-31. PubMed ID: 2527324
[TBL] [Abstract][Full Text] [Related]
28. Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer.
Geisler J; King N; Dowsett M; Ottestad L; Lundgren S; Walton P; Kormeset PO; Lønning PE
Br J Cancer; 1996 Oct; 74(8):1286-91. PubMed ID: 8883419
[TBL] [Abstract][Full Text] [Related]
29. Antitumor effect of a specific aromatase inhibitor, 1-methyl-androsta-1,4-diene-3,17-dione (atamestane), in female rats bearing DMBA-induced mammary tumors.
Nishino Y; Schneider MR; Michna H; el Etreby MF
J Steroid Biochem; 1989; 34(1-6):435-7. PubMed ID: 2533949
[TBL] [Abstract][Full Text] [Related]
30. Highly selective inhibition of estrogen biosynthesis by CGS 20267, a new non-steroidal aromatase inhibitor.
Bhatnagar AS; Häusler A; Schieweck K; Lang M; Bowman R
J Steroid Biochem Mol Biol; 1990 Dec; 37(6):1021-7. PubMed ID: 2149502
[TBL] [Abstract][Full Text] [Related]
31. Reversible inhibition of human placental microsomal aromatase by CGS 18320B and other non-steroidal compounds.
Bullion KA; Osawa Y; Braun DG
Endocr Res; 1990; 16(2):255-67. PubMed ID: 2140551
[TBL] [Abstract][Full Text] [Related]
32. Aromatase inhibitors: clinical pharmacology and therapeutic implications in breast cancer.
Pérez N; Borja J
J Int Med Res; 1992 Aug; 20(4):303-12. PubMed ID: 1387368
[TBL] [Abstract][Full Text] [Related]
33. Effect of treatment with 4-hydroxyandrostenedione on the peripheral conversion of androstenedione to estrone and in vitro tumor aromatase activity in postmenopausal women with breast cancer.
Reed MJ; Lai LC; Owen AM; Singh A; Coldham NG; Purohit A; Ghilchik MW; Shaikh NA; James VH
Cancer Res; 1990 Jan; 50(1):193-6. PubMed ID: 2293555
[TBL] [Abstract][Full Text] [Related]
34. Fadrozole hydrochloride, a new nontoxic aromatase inhibitor for the treatment of patients with metastatic breast cancer.
Falkson G; Raats JI; Falkson HC
J Steroid Biochem Mol Biol; 1992 Sep; 43(1-3):161-5. PubMed ID: 1388048
[TBL] [Abstract][Full Text] [Related]
35. The influence of aminoglutethimide and its analogue rogletimide on peripheral aromatisation in breast cancer.
MacNeill FA; Jones AL; Jacobs S; Lønning PE; Powles TJ; Dowsett M
Br J Cancer; 1992 Oct; 66(4):692-7. PubMed ID: 1419608
[TBL] [Abstract][Full Text] [Related]
36. Effective inhibition by low dose aminoglutethimide of peripheral aromatization in postmenopausal breast cancer patients.
Dowsett M; Santner SJ; Santen RJ; Jeffcoate SL; Smith IE
Br J Cancer; 1985 Jul; 52(1):31-5. PubMed ID: 4015950
[TBL] [Abstract][Full Text] [Related]
37. Anastrozole ('Arimidex') blocks oestrogen synthesis both peripherally and within the breast in postmenopausal women with large operable breast cancer.
Miller WR; Stuart M; Sahmoud T; Dixon JM
Br J Cancer; 2002 Oct; 87(9):950-5. PubMed ID: 12434282
[TBL] [Abstract][Full Text] [Related]
38. In vitro potency and selectivity of the non-steroidal androgen aromatase inhibitor CGS 16949A compared to steroidal inhibitors in the brain.
Wozniak A; Holman SD; Hutchison JB
J Steroid Biochem Mol Biol; 1992 Oct; 43(4):281-7. PubMed ID: 1390279
[TBL] [Abstract][Full Text] [Related]
39. The effects of oral 4-hydroxyandrostenedione on peripheral aromatisation in post-menopausal breast cancer patients.
MacNeill FA; Jacobs S; Dowsett M; Lonning PE; Powles TJ
Cancer Chemother Pharmacol; 1995; 36(3):249-54. PubMed ID: 7781147
[TBL] [Abstract][Full Text] [Related]
40. Relationship of body mass index with aromatisation and plasma and tissue oestrogen levels in postmenopausal breast cancer patients treated with aromatase inhibitors.
Lønning PE; Haynes BP; Dowsett M
Eur J Cancer; 2014 Apr; 50(6):1055-64. PubMed ID: 24507547
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
